As of March 31, 2025, cash, cash equivalents and marketable securities were $245.7 million. “The first quarter of 2025 was very productive for Cogent as our team focused on executing across our portfolio in preparation for three transformative data readouts this year. We look forward to reporting top-line results from our registration-directed SUMMIT trial with bezuclastinib in patients with nonadvanced systemic mastocytosis in July, followed later in the year with top-line results from our APEX and PEAK trials,” said Andrew Robbins, the Company’s President and Chief Executive Officer. “While we are preparing for a potential launch of bezuclastinib in 2026, we are also very proud of the progress we have made with our early-stage pipeline, including presentations from four distinct programs recently at the annual AACR conference.”
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences appoints Ray Frost as SVP, Market Access
- Cogent to present preclinical data from pipeline programs at AACR meeting
- JPMorgan healthcare analysts hold an analyst/industry conference call
- Coinbase initiated, Block upgraded: Wall Street’s top analyst calls
- Wolfe Research starts Blueprint Medicines at Outperform on bullish Ayvakit view